Bicycletx Limited

Immunogen, Inc.

Mersana Therapeutics, Inc.

Debiopharm International, S.a.

Sanofi

Bicyclerd Limited

Sanof Aventis

Peter U Park

Gemma Elizabeth Mudd

Liuhong Chen

Jutta Deckert

Lingyun Rui

Kevin McDonnell

Daniel J Tavares

Julianto Setiady

Timothy B Lowinger

Aleksandr V Yurkovetskiy

Natalya D Bodyak

Rachid Lani

Paul John Beswick

Thomas D Chittenden

Katerine Van Rietschoten

Punit Upadhyaya

Michael Rigby

Bianka Prinz

Eric Krauland

Nicholas Keen

Michael J DeVit

Gillian Payne

Hua-Xin Liao

Joseph G Sodroski

Rajeeva Singh

Vincent Mikol

Michael Skynner

Veronique Blanc

Laura L Poling

Gavin Bennett

Laura M Bartle

Anna Skaletskaya

Johanna Lahdenranta

Donald A Bergstrom

Pascale Lejeune

Viktor Golmakher

Tom Li Stephen

Helen Harrison

Harvey Che

Tara Gelb

Gillian Langford

Baptiste Aussedat

Stephen Blakemore

Michele Mayo

Véronique Blanc

Barton F Haynes

Michael J Devit

Eric M Krauland

Michele F Mayo

Yusuf Vohra

Viktor S Golmakher

Samuel Danishefsky

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

Bicyclic peptide ligands specific for Nectin-4

The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

Multimeric bicyclic peptide ligands

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

Bicyclic peptide ligands specific for CD137

Bicyclic peptide ligands specific for nectin-4

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.

Bicyclic peptide ligands specific for OX40

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.

Monoclonal antibodies against HER2 epitope and methods of use thereof

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.

CD37-binding molecules and immunoconjugates thereof

The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.

Heterotandem bicyclic peptide complexes

The present invention relates to a method of treating a cancer in a patient.

Methods for treating cancer

Bicyclic peptide ligand specific for CD137

This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.

NaPi2b-targeted antibody-drug conjugates and methods of use thereof

Growing community of inventors

Somerville, MA, United States of America

Peter U Park